Applicants: Gary A. Beaudry and Paul J. Maddon

U.S. Serial No.: Not Yet Known

Filed: Herewith

Page 2

33.

--34.

an amount effective to inhibit HIV infection of a CD4+ cell and a pharmaceutically acceptable carrier.--

--32. (New) A composition of matter comprising the CD4-gamma2 chimeric heavy chain homodimer of claim 30 and a toxin linked thereto.--

(New) The composition of claim 32, wherein the toxin is the deglycosylated A chain of ricin, domains II or III of Pseudomonas exotoxin A, or Diphtheria toxin.--

(New) A diagnostic reagent comprising the CD4-gamma2 chimeric heavy chain homodimer of claim 30 and a detectable marker linked thereto.--

(New) The diagnostic reagent of claim 34 wherein the detectable marker is a radioisotope, chromophore or fluorophore.--

- --36. (New) A CD4-IgG2 chimeric heterotetramer, the heavy chains of which are encoded by the expression vector designated CD4-IgG2HC-propMV (ATCC No. 75193).--
- --37. (New) A CD4-IgG2 chimer c heterotetramer, the light chains of which are encoded by the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194).--
- --38. (New) A CD4-IgG2 chimeric heterotetramer, the heavy and the light chains of which are encoded by the expression vector designated CD4-IgG2HC-pRcCMV (ATCC No. 75193) and the expression vector designated CD4-kLC-pRcCMV (ATCC No. 75194), respectively.--

Suts B'

--35.